| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating Costs and Expenses: | |||||||||
License revenue, net | |||||||||
- | - | - | - | - | - | - | - | - | 2,125 |
Grant revenue | |||||||||
- | - | - | - | - | - | - | - | - | 489 |
Total Revenues | |||||||||
- | - | - | - | - | - | - | - | - | 2,614 |
General and administrative | |||||||||
4,580 | 5,727 | 7,467 | 10,143 | 8,074 | 6,013 | 5,832 | 5,012 | 2,588 | 2,117 |
Research and development | |||||||||
11,083 | 11,844 | 18,784 | 29,109 | 32,906 | 14,489 | 6,507 | 12,287 | 3,340 | 1,580 |
Total Operating Costs and Expenses | |||||||||
15,663 | 17,571 | 26,251 | 39,252 | 40,980 | 20,502 | 12,339 | 17,299 | 5,928 | 3,697 |
Loss from Operations | |||||||||
-15,663 | -17,571 | -26,251 | -39,252 | -40,980 | -20,502 | -12,339 | -17,299 | - | - |
Loss from Operations | |||||||||
- | - | - | - | - | - | - | - | -5,928 | -1,083 |
Other Income : | |||||||||
Change in fair value of warrant liability | |||||||||
0 | -4,083 | -10,738 | -11,412 | 3,811 | -620 | 0 | 0 | - | - |
Other income | |||||||||
- | - | - | - | - | 95 | -12 | -18 | 22 | - |
Warrant expense | |||||||||
- | - | - | - | - | - | - | - | 1,492 | - |
Change in fair value of warrant liability | |||||||||
- | - | - | - | - | - | - | - | 242 | - |
Warrant expense | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Change in fair value of warrant liability | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Impairment loss on equipment | |||||||||
- | - | - | - | - | - | - | - | - | 121 |
Interest income | |||||||||
283 | 67 | 21 | 37 | 6 | 3 | 33 | 33 | 14 | 0 |
Other income | |||||||||
- | - | - | - | - | - | - | - | - | 9 |
Total Other Income | |||||||||
283 | 4,150 | 10,759 | 11,449 | -3,805 | 718 | 21 | 15 | -1,698 | -112 |
Loss from Continuing Operations | |||||||||
- | - | - | - | - | - | - | -17,284 | -7,626 | -1,195 |
Income from Discontinued Operations | |||||||||
- | - | - | - | - | - | - | 216 | -523 | -516 |
Net Loss | |||||||||
-15,380 | -13,421 | -15,492 | -27,803 | -44,785 | -19,784 | -12,318 | -17,068 | - | - |
Net Loss Attributable to Non-controlling Interest | |||||||||
-77 | -54 | -318 | -548 | -1,048 | 0 | -1 | 0 | - | - |
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries | |||||||||
-15,303 | -13,367 | -15,174 | -27,255 | -43,737 | -19,784 | -12,317 | -17,068 | -8,149 | -1,711 |
Preferred Stock Dividends, Income Statement Impact | |||||||||
248 | 243 | 73 | 0 | 0 | - | - | - | - | - |
Net Loss Attributable to Common Stockholders | |||||||||
-16,076 | -25,291 | -22,136 | -27,255 | -43,737 | - | - | - | - | - |
Net Loss Per Share - Basic and Dilutive (in dollars per share) | |||||||||
- | - | - | - | - | - | - | -0.50 | -0.27 | -0.06 |
Discontinued operations (in dollars per share) | |||||||||
- | - | - | - | - | - | - | 0.01 | -0.02 | -0.02 |
Net Loss Per Share - Basic and Dilutive | |||||||||
-0.98 | -4.06 | -6.23 | -0.29 | -0.54 | -0.32 | -0.27 | -0.49 | -0.29 | -0.08 |
Weighted average number of shares outstanding during the period - Basic and Dilutive | |||||||||
16,438 | 6,232 | 3,553 | 94,290 | 80,705 | 61,945 | 45,667 | 34,896 | 27,710 | - |
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares) | |||||||||
- | - | - | - | - | - | - | - | - | 22,393 |
Series B Preferred Stock [Member] | |||||||||
Net Loss Attributable to Non-controlling Interest | |||||||||
0 | 0 | 0 | - | - | - | - | - | - | - |
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries | |||||||||
0 | 0 | 0 | - | - | - | - | - | - | - |
Preferred Stock Dividends, Income Statement Impact | |||||||||
525 | 11,681 | 0 | - | - | - | - | - | - | - |
Series A Preferred Stock [Member] | |||||||||
Preferred Stock Dividends, Income Statement Impact | |||||||||
200 | 200 | 6,962 | - | - | - | - | - | - | - |